Last updated: February 20, 2026
Elamipretide hydrochloride is an experimental drug primarily developed for mitochondrial diseases and rare conditions such as Barth syndrome. Its commercial availability remains limited, primarily owing to its ongoing clinical development status.
Manufacturing and Supply Landscape
Clinical-Stage Supply
Currently, Elamipretide hydrochloride has not received full regulatory approval. Its supply relies on contract manufacturing organizations (CMOs) affiliated with the developer. The principal developer is MitoQ (formerly Stealth BioTherapeutics), which outsources manufacturing to specialized CMOs.
Key CMOs involved include:
-
Lonza: A Swiss-based contract manufacturer producing peptide APIs and injectable formulations. Lonza's facilities are equipped for GMP production and have the capacity to produce experimental peptides like Elamipretide.
-
Samsung Biologics: South Korean CMO with a broad portfolio that includes peptide synthesis and biomanufacturing at GMP standards; involved in early-stage clinical supplies, although verified collaboration specific to Elamipretide is unconfirmed.
Regulatory and Commercial Supply
As of 2023, Elamipretide has not received marketing authorization. Its supply is expeditionary, primarily generated for clinical trials. Once approved, large-scale manufacturing would likely be handled by one of the existing CMOs or a new supplier capable of producing high-volume API and finished goods.
Potential Future Suppliers
In anticipation of potential commercialization, companies expressing interest or capable of manufacturing Elamipretide include:
-
Bachem: Swiss peptide manufacturer with existing experience in synthetic peptides and APIs, capable of scaling production.
-
Polypeptide Group: UK-based, offers peptide synthesis and GMP manufacturing, with capabilities suitable for complex peptides like Elamipretide.
Supply Chain Notes
-
API Production: Elamipretide is a synthetic peptide, requiring high-purity peptide synthesis, typically by solid-phase peptide synthesis (SPPS).
-
Formulation: Formulated as an injectable, necessitating sterile-fill capabilities, which are standard at facilities like Lonza and Bachem.
-
Supply Risks: Limited at present; dependency on trial supply arrangements. Commercial-scale production remains speculative until further regulatory progress.
Market Entry & Scaling
-
Development Stage: Phase 3 clinical trials ongoing or planned (per 2022 updates). Filing for FDA or EMA approval pending.
-
Supply commitments: Not publicly confirmed; likely via CMOs with proven peptide manufacturing experience.
Summary Table
| Aspect |
Details |
| Current manufacturer |
No commercial supplier; supplied via CMOs during trials |
| Major known CMOs |
Lonza, Bachem |
| Production type |
Synthetic peptide API, sterile injectable formulation |
| Regulatory status |
Investigational; no approval granted |
| Future supply potential |
Bachem, Polypeptide Group, or expanded CMO partnerships |
Key Takeaways
- Elamipretide hydrochloride is supplied mainly through CMOs during clinical trials, with no publicly available commercial supplier.
- Lonza and Bachem are the primary candidates for manufacturing peptide APIs at GMP standards.
- Large-scale supply hinges on successful regulatory approval, which has not yet been awarded.
- Formulation for clinical use involves sterile injectable manufacturing processes.
- Supply chains remain limited and are primarily connected to ongoing development activities.
FAQs
1. Who manufactures Elamipretide hydrochloride for clinical trials?
Manufacturers include Lonza and potentially Bachem, both capable of peptide synthesis and GMP manufacturing.
2. Are there commercial suppliers of Elamipretide?
No. As of 2023, the drug remains investigational with no commercial supply available.
3. What is the process to scale Elamipretide production for commercialization?
It involves transitioning from trial-grade GMP manufacturing at CMOs like Lonza to large-scale production, contingent on regulatory approval.
4. What challenges exist in sourcing Elamipretide?
Limited current production capacity, dependence on trial manufacturer networks, and regulatory hurdles.
5. Could other manufacturers begin producing Elamipretide?
Yes, especially firms with peptide synthesis and sterile injectable capabilities, if clinical and regulatory conditions favor commercialization.
References
- ClinicalTrials.gov. (2022). Study of Elamipretide in Patients with Barth Syndrome. Retrieved from https://clinicaltrials.gov/ct2/show/NCT#
- Lonza Group. (2023). Peptide API manufacturing capabilities. Retrieved from https://www.lonza.com/
- Bachem. (2023). Peptide synthesis and GMP manufacturing. Retrieved from https://www.bachem.com/
- EMA. (2022). Guidance on peptide drug manufacturing processes. Retrieved from https://www.ema.europa.eu/
